Dextech Medical AB (XSAT:DEX)

Market Cap	129.40M
Revenue (ttm)	3.47M
Net Income (ttm)	-4.96M
Shares Out	18.49M
EPS (ttm)	-0.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,304
Average Volume	10,884
Open	7.10
Previous Close	7.10
Day's Range	6.80 - 7.10
52-Week Range	3.62 - 11.00
Beta	1.38
RSI	41.44
Earnings Date	Nov 3, 2025

About Dextech Medical AB

Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer. Its principal product candidate is OsteoDex that has completed phase IIb clinical trial for the treatment of skeletal metastases in castration resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, to treat acromegaly, neuroendocrine ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 1
• Stock Exchange: Spotlight Stock Market
• Ticker Symbol: DEX

Financial Performance

In 2025, Dextech Medical AB's revenue was 3.22 million, a decrease of -40.15% compared to the previous year's 5.39 million. Losses were -4.84 million, 2.96% more than in 2024.